按产品类型、最终用户、技术、分销管道和应用分類的即时血脂检测市场—2025-2032年全球预测

预计到 2032 年，即时血脂检测市场规模将达到 5.4932 亿美元，复合年增长率为 6.44%。

关键市场统计数据
基准年 2024	3.3333亿美元
预计年份：2025年	3.5486亿美元
预测年份 2032	5.4932亿美元
复合年增长率 (%)	6.44%

本文简要概述了技术进步、临床需求和监管政策的明确性如何重塑照护现场血脂检测的交付模式。

照护现场血脂检测已成为现代心血管代谢疾病预防保健的关键组成部分，能够更快地进行风险评估并简化临床工作流程。检测化学、设备小型化和介面设计的进步，共同降低了在传统中心检查室之外提供临床实用血脂谱所需的时间和复杂性。因此，临床医生、照护团队和患者现在都期望在就诊时就能获得更快、更具指导意义的三酸甘油酯和胆固醇值。

快速的技术创新、分散式医疗模式以及不断变化的医疗保健系统奖励，正在从根本上改变照护现场血脂检测的普及和应用。

在技​​术创新和不断发展的诊疗路径的推动下，照护现场脂质诊断领域正经历变革性的转变。新型检测法以及日益紧凑的桌上型和携带式分析仪缩小了与中心检查室平台之间的性能差距，使得在照护现场更可靠的血脂检查成为可能。这些技术进步辅以试剂稳定性的提升和工作流程的简化，从而减轻了非检查室人员的工作负担。

本文分析了近期关税如何重塑照护现场血脂诊断生态系统的供应链策略和采购方式。

美国近期实施的关税政策为照护现场血脂检测设备及耗材的生产商和供应商带来了复杂的经营环境。部分进口诊断组件关税的提高增加了依赖全球供应链的营业单位的成本，促使它们重新评估筹资策略和总到岸成本。因此，采购部门更加重视供应商多元化和合约保障，以维持利润率并确保产品供应。

细分市场洞察揭示了产品类型、使用者环境、技术、通路和临床应用如何共同决定产品采用趋势。

产品细分洞察显示，市场分为耗材和仪器两大类。耗材包括品管、试剂盒和试剂等关键要素，这些要素决定了检测性能和批间一致性。而仪器则包括适用于临床和实验室环境的桌上型分析仪，以及针对速度和便携性进行最佳化的携带式分析仪。不断变化的采购行为使消费者更加重视整体拥有成本和检验耗材的供应稳定性，因此，能够确保试剂长期供应并提供简单易用的仪器维护流程的製造商将获得竞争优势。

区域比较分析：阐释不同法规结构、基础设施成熟度和支付方环境对照护现场血脂检测部署路径的影响

区域趋势将影响照护现场血脂检测的推广路径和营运策略。在美洲，由于相对成熟的医疗保健体系和强大的商业分销系统，临床网络优先将快速诊断整合到基层医疗和社区诊所中。这种环境促进了桌上型和携带式分析仪的普及，这些分析仪能够提高工作流程效率并增强病人参与。此外，强大的诊断检查室基础也为混合部署模式提供了可能，在这种模式下，检测方法会与中心检查室的参考方法检验。

如何透过检测方法创新、整合服务模式、策略伙伴关係以及严谨的临床证据产生来建构竞争优势

照护现场血脂检测领域的竞争格局由产品创新、策略联盟和临床疗效声明三者共同驱动。主要企业正大力投资于检测方法开发和使用者体验工程，以透过准确性、速度和整合能力脱颖而出。随着企业寻求确保原料供应并降低贸易政策波动风险，与试剂和组件供应商建立供应链联盟和共同开发契约正变得越来越普遍。

为製造商和医疗系统领导者制定优先策略行动，以增强韧性、加速推广应用并展现临床和商业性价值。

产业领导者应优先考虑供应链多元化和生产弹性，以应对贸易政策波动和零件短缺的风险。投资建造区域组装中心并寻找关键试剂和仪器组件的替代供应商，可以显着降低关税和物流波动带来的风险。同时，他们也应评估能够简化组件复杂性的产品设计，从而实现灵活生产并根据需要快速更新法规。

我们采用严谨的混合调查方法，结合相关人员访谈、监管审查、设备基准化分析和专家检验，为策略决策提供支援。

本分析整合了一项混合方法研究的成果，该研究结合了对关键产业相关人员的定性访谈以及对监管、临床和专利文献的系统性回顾。研究透过与临床实验室主任、采购人员、医疗设备工程师和支付者进行结构化对话，检验了营运挑战和实施标准，并将这些对话作为主要资讯来源。为了确保技术和临床的严谨性，研究还参考了公开的监管文件、临床试验註册资讯和同行评审的出版物，对这些观点进行了三角验证。

简要概述强调了整合产品、临床证据和供应链策略对于充分发挥照护现场血脂检测潜力的迫切需求。

照护现场血脂检测正处于转折点，其发展动力源于技术进步、医疗分散化趋势以及临床医生和患者期望的转变。设备设计、耗材可靠性和分销策略的相互作用将决定能否在各种临床环境中有效推广应用。同时，不断变化的贸易政策和供应链现状也要求企业建立更具韧性的商业模式和更切合实际的生产方案。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 将基于人工智慧的分析技术整合到照护现场血脂检测设备中，以实现心血管风险预测评估。
• 在基层医疗机构中推广使用携带式血脂检测平台进行早期胆固醇管理
• 开发一种结合血脂谱和生物标记的多重照护现场分析仪，用于全面的心血管风险分层
• 监管核准对新兴市场快速携带式血脂检测系统商业化的影响
• 诊断公司与远端医疗服务提供者合作，为慢性疾病患者提供远距血脂监测解决方案
• 微流体晶片技术可减少照护现场血脂检测的检体用量并缩短检测週期。
• 照护现场设备製造商与健康保险公司进行策略合作，将血脂检测纳入预防保健方案。
• 消费者对具备行动应用程式连接功能的家用侧向层析血脂检测套组的需求日益增长，这类试剂盒能够与医生即时共用数据。
• 基于酵素的生物感测器的创新提高了照护现场血脂定量检测的灵敏度和特异性。
• 领先的诊断设备製造商针对资源有限的诊所，制定了以经济高效的方式推广血脂检测解决方案的打入市场策略。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依产品类型分類的即时血脂检测市场

• 消耗品
  • 控制
  • 成套工具
  • 试剂
• 装置
  • 桌上型分析仪器
  • 手持式分析仪

9. 依最终用户分類的即时血脂检测市场

• 诊所
• 诊断实验室
• 居家检测
• 医院

10. 依技术分類的即时血脂检测市场

• 层析法
• 比色法
• 酵素法
• 免疫检测

11. 按分销管道分類的即时血脂检测市场

• 诊断实验室
• 电子商务
• 医院药房
• 零售药房

第十二章：按应用分類的即时血脂检测市场

• 心血管疾病风险评估
• 糖尿病管理
• 预防性筛检

13. 按地区分類的即时血脂检测市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章 按群体分類的即时血脂检测市场

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

15. 各国即时血脂检测市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Abbott Laboratories
  • Roche Diagnostics International AG
  • Siemens Healthineers AG
  • Nova Biomedical Corporation
  • PTS Diagnostics, LLC
  • EKF Diagnostics Holdings plc
  • Trividia Health, Inc.
  • Chembio Diagnostics, Inc.
  • Arkray, Inc.
  • Meridian Bioscience, Inc.

The POC Lipid Testing Market is projected to grow by USD 549.32 million at a CAGR of 6.44% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 333.33 million
Estimated Year [2025]	USD 354.86 million
Forecast Year [2032]	USD 549.32 million
CAGR (%)	6.44%

A concise overview of how technological advances, clinical demand, and regulatory clarity are reshaping point-of-care lipid testing delivery models

Point-of-care lipid testing has emerged as a pivotal component in modern preventive cardiometabolic care, enabling more immediate risk assessment and streamlined clinical workflows. Advances in assay chemistry, device miniaturization, and interface design have collectively reduced the time and complexity required to deliver clinically actionable lipid profiles outside traditional central laboratories. As a result, clinicians, care teams, and patients now expect faster access to triglyceride and cholesterol metrics that can inform same-encounter decision-making.

Moreover, the convergence of remote monitoring, telehealth, and decentralized diagnostic strategies is reshaping how lipid testing is deployed in ambulatory settings, community clinics, and increasingly within the home. Regulatory authorities have clarified pathways for point-of-care devices while payers and health systems explore reimbursement and value pathways that reflect the potential for earlier intervention and reduced downstream costs. At the same time, laboratory professionals continue to emphasize the need for rigorous quality assurance, method comparability, and robust clinical validation to preserve diagnostic confidence.

Taken together, these dynamics create both opportunity and obligation for manufacturers, distributors, and healthcare providers. Industry players must balance speed-to-market with demonstrable accuracy, user-centric design, and integration capabilities that support electronic health record interoperability and clinical decision support. As adoption grows, stakeholders who proactively address operational, regulatory, and clinical alignment will be best positioned to capitalize on the shift toward more immediate lipid assessment.

How rapid innovation, decentralized care models, and evolving health system incentives are fundamentally altering point-of-care lipid testing adoption and delivery

The landscape for point-of-care lipid diagnostics is experiencing transformative shifts driven by technological innovation and evolving care pathways. New assay modalities and increasingly compact benchtop and handheld analyzers have narrowed the performance gap with central laboratory platforms, enabling more reliable lipid panels at the point of care. These technical gains are complemented by improved reagent stability and streamlined workflow designs that lower the operational burden on non-laboratory personnel.

Simultaneously, the rise of home testing and patient-centered care models has prompted device makers to focus on usability, connectivity, and data security. Vendors are investing in digital ecosystems that link test results to mobile apps and telehealth platforms, which supports shared decision-making between patients and clinicians. In parallel, clinical practice guidelines and payer policies are adapting to recognize the role of rapid lipid assessment in chronic disease management and preventive screening, which influences procurement priorities and deployment strategies.

Supply chain resilience has also become a strategic imperative, with manufacturers diversifying sourcing and considering regional production hubs to mitigate disruptions. As adoption broadens, partnership models are shifting away from one-size-fits-all sales toward outcome-oriented collaborations that offer bundled device-and-service solutions. Consequently, the market is moving toward a more integrated, patient-focused diagnostic paradigm where speed, quality, and interoperability determine long-term value.

An analytical review of how recent tariff measures have reshaped supply chain strategies and procurement approaches across the point-of-care lipid diagnostics ecosystem

Recent tariff measures implemented in the United States have created a complex environment for manufacturers and suppliers of point-of-care lipid testing equipment and consumables. Increased duties on certain imported diagnostic components have amplified costs for entities reliant on global supply chains, prompting organizations to re-evaluate sourcing strategies and total landed costs. As a direct result, procurement teams are placing greater emphasis on supplier diversification and contractual protections to preserve margin and maintain product availability.

In response, some vendors are accelerating discussions around nearshoring and local assembly to reduce exposure to cross-border tariff volatility. These shifts are not solely procurement-driven; they also influence product design choices as companies seek to reduce reliance on tariffed components by redesigning kits and instruments for regional manufacturing compatibility. At the same time, distributors and healthcare providers are responding by negotiating longer-term agreements and inventory buffers to smooth operational continuity.

Payment and contracting considerations are also adapting, since higher input costs can impact pricing structures and the relative attractiveness of bundled service offerings. Therefore, commercial teams and health system purchasers are increasing the sophistication of total cost assessments, taking into account logistics, regulatory compliance, and potential duties. Ultimately, tariff-related pressures are accelerating strategic shifts toward supply-chain resilience, regional manufacturing partnerships, and contract designs that hedge against future trade-policy changes.

Segment-specific insights revealing how product types, user settings, technologies, distribution pathways, and clinical applications jointly dictate adoption dynamics

Insight into product segmentation reveals that the market is bifurcated between consumables and instruments, with consumables encompassing essential elements such as controls, kits, and reagents that determine assay performance and lot-to-lot consistency, while instruments include both benchtop analyzers suited for clinic and laboratory environments and handheld analyzers optimized for speed and portability. Shifts in purchasing behavior often prioritize total cost of ownership and the availability of validated consumable supplies, so manufacturers that secure long-term reagent supply and deliver intuitive instrument maintenance protocols gain a competitive edge.

From an end-user perspective, adoption patterns vary across clinics, diagnostic laboratories, home testing settings, and hospitals. Clinical decision workflows in hospital and large outpatient settings tend to demand higher throughput and integration with existing laboratory information systems, whereas clinics and home testing emphasize ease of use, minimal sample handling, and rapid result turnaround to support point-of-care consultations. Diagnostic laboratories continue to act as quality hubs, often validating and benchmarking point-of-care outputs to ensure method concordance and to support clinician confidence.

Technology segmentation further highlights the diversity of approaches to lipid measurement. Chromatographic methods and immunoassays offer high analytical specificity and are frequently used in centralized contexts, while colorimetric and enzymatic methods provide simpler, faster pathways to lipid quantification at the point of care. Each technology presents trade-offs among accuracy, cost, and operational complexity; therefore, product positioning must align with the clinical setting and the skill level of intended users.

Distribution channels also shape accessibility and adoption. Diagnostic laboratories, e-commerce platforms, hospital pharmacies, and retail pharmacies each play distinct roles in getting devices and consumables into clinical and consumer hands. E-commerce accelerates direct-to-consumer access and simplifies repeat consumable purchases, whereas hospital and retail pharmacies enable integration into institutional procurement and patient support programs. Finally, application-driven demand-spanning cardiovascular risk assessment, diabetes management, and preventive screening-frames clinical utility and the types of outcome data purchasers require for reimbursement and guideline adoption. Manufacturers that tailor solutions to these application needs and distribution realities can better align product development and commercialization efforts with end-user expectations.

A regional comparative analysis explaining how differing regulatory frameworks, infrastructure maturity, and payer landscapes influence point-of-care lipid testing trajectories

Regional dynamics shape both the adoption trajectory and operational strategies for point-of-care lipid testing. In the Americas, clinical networks emphasize rapid diagnostics integration into primary care and community clinics, supported by relatively mature reimbursement frameworks and a strong private-sector distribution system. These conditions encourage adoption of both benchtop and handheld analyzers that can demonstrate workflow efficiencies and improved patient engagement. Additionally, a robust base of diagnostic labs provides opportunities for hybrid deployment models where point-of-care platforms are validated against central laboratory reference methods.

Across Europe, the Middle East, and Africa, regulatory and reimbursement environments are heterogeneous, driving a more localized approach to market entry. In parts of Europe, well-established health technology assessment mechanisms prioritize clinical validation and cost-effectiveness evidence, which favors devices that can demonstrate quality and outcome benefits. Meanwhile, in the Middle East and Africa, infrastructure gaps and variability in laboratory capacity create demand for portable, easy-to-use devices and consumables that can operate with limited facilities and supply chain constraints. Manufacturers should therefore align regulatory strategies and support models with local health system needs, leveraging partnerships with regional distributors and clinical networks.

Asia-Pacific presents a mix of high-volume urban centers with advanced diagnostic infrastructure and expansive rural areas where decentralized testing can deliver substantial public health value. A strong manufacturing base in several countries supports both regional production and export opportunities, while rapid digital adoption facilitates remote monitoring and integration with national health initiatives. In this region, payers and providers are increasingly receptive to innovations that reduce clinical bottlenecks and enhance chronic disease management, making Asia-Pacific an important locus for scalable deployment and iterative product refinement.

How competitive advantage is being forged through assay innovation, integrated service models, strategic partnerships, and rigorous clinical evidence generation

Competitive dynamics in the point-of-care lipid testing space are defined by a mix of product innovation, strategic partnerships, and claims to clinical validation. Leading organizations invest heavily in assay development and usability engineering to differentiate through accuracy, speed, and integration capabilities. Supply-chain partnerships and co-development agreements with reagent and component suppliers are increasingly common as firms seek to secure raw materials and mitigate risk from trade-policy shifts.

In addition to technical differentiation, commercialization strategies vary widely. Some firms focus on comprehensive service offerings that bundle devices with consumables, training, and remote quality oversight, while others pursue a more modular approach that emphasizes low-cost consumables and broad distribution through e-commerce and pharmacy channels. Strategic alliances with healthcare networks, telehealth providers, and electronic health record vendors are shaping interoperability and care pathway alignment, which in turn influence purchasing decisions among health systems and clinics.

Regulatory compliance and evidence generation remain central to competitive advantage. Companies that prioritize robust clinical evaluation and establish clear pathways for regulatory clearance and post-market surveillance build trust with clinical stakeholders. Moreover, firms that demonstrate responsiveness to payer expectations-by generating real-world evidence of clinical utility in cardiovascular risk assessment, diabetes management, and preventive screening-can materially strengthen their market positioning. Ultimately, success hinges on marrying credible science with scalable commercial models and resilient supply chains.

Prioritized strategic actions for manufacturers and health system leaders to strengthen resilience, accelerate adoption, and demonstrate clinical and commercial value

Industry leaders should prioritize supply-chain diversification and manufacturing flexibility to hedge against trade-policy disruptions and component shortages. Investing in regional assembly hubs and qualifying alternate suppliers for critical reagents and instrument parts can materially reduce exposure to tariff and logistics volatility. At the same time, organizations should evaluate product designs that simplify component complexity, enabling more adaptable production footprints and faster regulatory updates when needed.

Second, companies must accelerate user-centric design and connectivity features for both benchtop and handheld analyzers to drive adoption in decentralized settings and the home. Streamlined workflows, integrated quality controls, and secure data transfer to electronic health records will differentiate offerings and support clinician acceptance. Complementing these technical improvements with structured training programs and remote technical support will reduce user errors and enhance clinical confidence.

Third, manufacturers should deepen engagement with payers, professional societies, and health systems to generate the clinical evidence required for guideline inclusion and reimbursement. Collaborative pilot programs that measure impact on clinical decision-making and downstream outcomes will strengthen value propositions. Parallel commercial strategies should explore bundled service models that combine device placement, consumable supply, and performance monitoring to simplify procurement and improve adherence.

Finally, pursue partnerships that extend beyond traditional distribution-linking with telehealth platforms, chronic care management vendors, and pharmacy networks-to create integrated care pathways. These alliances can expand reach, support patient retention for longitudinal monitoring, and create differentiated offerings that capture greater downstream value.

A rigorous mixed-methods research approach combining stakeholder interviews, regulatory review, device benchmarking, and expert validation to support strategic decision-making

This analysis synthesizes insights derived from a mixed-methods research approach that combines primary qualitative interviews with key industry stakeholders and systematic review of regulatory, clinical, and patent literature. Primary inputs included structured conversations with clinical laboratory directors, procurement leaders, device engineers, and payers to validate operational pain points and adoption criteria. These perspectives were triangulated with publicly available regulatory filings, clinical trial registries, and peer-reviewed publications to ensure technical and clinical accuracy.

Quantitative elements of the methodology comprised device performance benchmarking and comparative assessments of assay principles, focusing on analytical sensitivity, specificity, and user workflow metrics. Supply-chain and trade-policy analyses were informed by customs and tariff schedules, logistics reports, and manufacturer disclosures to capture cost and availability implications. Throughout the process, findings were reviewed by an external panel of clinical and technical experts to stress-test assumptions and identify blind spots.

Limitations of the research include variability in regional data transparency and differences in clinical practice patterns that can influence adoption scenarios. To mitigate these constraints, the methodology emphasizes qualitative contextualization and cross-validation across multiple independent sources. The result is a pragmatic, evidence-focused assessment intended to support strategic decision-making rather than deterministic market projections.

A concise synthesis highlighting the imperative for integrated product, clinical evidence, and supply-chain strategies to realize point-of-care lipid testing potential

Point-of-care lipid testing stands at an inflection point, propelled by technological improvements, a shift toward decentralized care, and evolving expectations from clinicians and patients. The interplay between instrument design, consumable reliability, and distribution strategies will determine which solutions scale effectively across diverse clinical settings. Concurrently, trade-policy shifts and supply-chain realities necessitate more resilient commercial models and pragmatic manufacturing choices.

For stakeholders across the value chain, the imperative is clear: align product development with real-world clinical workflows, invest in evidence generation that addresses payer and guideline requirements, and construct flexible supply chains that support continuity of care. By doing so, organizations can unlock the clinical and operational benefits of rapid lipid assessment while safeguarding quality and accessibility. Ultimately, the most successful players will be those that integrate robust science, user-centric design, and adaptive commercial strategies to meet the needs of an increasingly decentralized diagnostic environment.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Integration of AI-powered analysis in point-of-care lipid testing devices enabling predictive cardiovascular risk assessments
• 5.2. Rising adoption of portable lipid testing platforms in primary care settings for early cholesterol management
• 5.3. Development of multiplex point-of-care analyzers combining lipid profiles with biomarkers for comprehensive cardio risk stratification
• 5.4. Impact of regulatory approvals on the commercialization of rapid handheld lipid testing systems in emerging markets
• 5.5. Collaboration between diagnostics companies and telehealth providers to deliver remote lipid monitoring solutions for chronic patients
• 5.6. Emergence of microfluidic chip technology to reduce sample volume and turnaround time in point-of-care lipid assays
• 5.7. Strategic partnerships between point-of-care device manufacturers and health insurers to integrate lipid testing into preventive care packages
• 5.8. Increasing demand for home-based lateral flow lipid testing kits integrated with mobile apps for real-time data sharing with physicians
• 5.9. Innovation in enzyme-based biosensors for enhanced sensitivity and specificity in point-of-care lipid quantification
• 5.10. Market entry strategies of major diagnostics firms focusing on cost-effective lipid testing solutions for resource-limited clinics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. POC Lipid Testing Market, by Product Type

• 8.1. Consumables
  • 8.1.1. Controls
  • 8.1.2. Kits
  • 8.1.3. Reagents
• 8.2. Instruments
  • 8.2.1. Benchtop Analyzers
  • 8.2.2. Handheld Analyzers

9. POC Lipid Testing Market, by End User

• 9.1. Clinics
• 9.2. Diagnostic Labs
• 9.3. Home Testing
• 9.4. Hospitals

10. POC Lipid Testing Market, by Technology

• 10.1. Chromatographic Methods
• 10.2. Colorimetric Methods
• 10.3. Enzymatic Methods
• 10.4. Immunoassays

11. POC Lipid Testing Market, by Distribution Channel

• 11.1. Diagnostic Laboratories
• 11.2. E-commerce
• 11.3. Hospital Pharmacies
• 11.4. Retail Pharmacies

12. POC Lipid Testing Market, by Application

• 12.1. Cvd Risk Assessment
• 12.2. Diabetes Management
• 12.3. Preventive Screening

13. POC Lipid Testing Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. POC Lipid Testing Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. POC Lipid Testing Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Abbott Laboratories
  • 16.3.2. Roche Diagnostics International AG
  • 16.3.3. Siemens Healthineers AG
  • 16.3.4. Nova Biomedical Corporation
  • 16.3.5. PTS Diagnostics, LLC
  • 16.3.6. EKF Diagnostics Holdings plc
  • 16.3.7. Trividia Health, Inc.
  • 16.3.8. Chembio Diagnostics, Inc.
  • 16.3.9. Arkray, Inc.
  • 16.3.10. Meridian Bioscience, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL POC LIPID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL POC LIPID TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL POC LIPID TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL POC LIPID TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS POC LIPID TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL POC LIPID TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. POC LIPID TESTING MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. POC LIPID TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. POC LIPID TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL POC LIPID TESTING MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL POC LIPID TESTING MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONTROLS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONTROLS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONTROLS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONTROLS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONTROLS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL POC LIPID TESTING MARKET SIZE, BY CONTROLS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL POC LIPID TESTING MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL POC LIPID TESTING MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL POC LIPID TESTING MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL POC LIPID TESTING MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL POC LIPID TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL POC LIPID TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL POC LIPID TESTING MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL POC LIPID TESTING MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL POC LIPID TESTING MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL POC LIPID TESTING MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL POC LIPID TESTING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL POC LIPID TESTING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL POC LIPID TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL POC LIPID TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL POC LIPID TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL POC LIPID TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL POC LIPID TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL POC LIPID TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL POC LIPID TESTING MARKET SIZE, BY HANDHELD ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL POC LIPID TESTING MARKET SIZE, BY HANDHELD ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL POC LIPID TESTING MARKET SIZE, BY HANDHELD ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL POC LIPID TESTING MARKET SIZE, BY HANDHELD ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL POC LIPID TESTING MARKET SIZE, BY HANDHELD ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL POC LIPID TESTING MARKET SIZE, BY HANDHELD ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL POC LIPID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL POC LIPID TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL POC LIPID TESTING MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL POC LIPID TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL POC LIPID TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL POC LIPID TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL POC LIPID TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOME TESTING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOME TESTING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOME TESTING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOME TESTING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOME TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOME TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL POC LIPID TESTING MARKET SIZE, BY CHROMATOGRAPHIC METHODS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL POC LIPID TESTING MARKET SIZE, BY CHROMATOGRAPHIC METHODS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL POC LIPID TESTING MARKET SIZE, BY CHROMATOGRAPHIC METHODS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL POC LIPID TESTING MARKET SIZE, BY CHROMATOGRAPHIC METHODS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL POC LIPID TESTING MARKET SIZE, BY CHROMATOGRAPHIC METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL POC LIPID TESTING MARKET SIZE, BY CHROMATOGRAPHIC METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL POC LIPID TESTING MARKET SIZE, BY COLORIMETRIC METHODS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL POC LIPID TESTING MARKET SIZE, BY COLORIMETRIC METHODS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL POC LIPID TESTING MARKET SIZE, BY COLORIMETRIC METHODS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL POC LIPID TESTING MARKET SIZE, BY COLORIMETRIC METHODS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL POC LIPID TESTING MARKET SIZE, BY COLORIMETRIC METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL POC LIPID TESTING MARKET SIZE, BY COLORIMETRIC METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL POC LIPID TESTING MARKET SIZE, BY ENZYMATIC METHODS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL POC LIPID TESTING MARKET SIZE, BY ENZYMATIC METHODS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL POC LIPID TESTING MARKET SIZE, BY ENZYMATIC METHODS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL POC LIPID TESTING MARKET SIZE, BY ENZYMATIC METHODS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL POC LIPID TESTING MARKET SIZE, BY ENZYMATIC METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL POC LIPID TESTING MARKET SIZE, BY ENZYMATIC METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL POC LIPID TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL POC LIPID TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL POC LIPID TESTING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL POC LIPID TESTING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL POC LIPID TESTING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL POC LIPID TESTING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL POC LIPID TESTING MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL POC LIPID TESTING MARKET SIZE, BY E-COMMERCE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL POC LIPID TESTING MARKET SIZE, BY E-COMMERCE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL POC LIPID TESTING MARKET SIZE, BY E-COMMERCE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL POC LIPID TESTING MARKET SIZE, BY E-COMMERCE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL POC LIPID TESTING MARKET SIZE, BY E-COMMERCE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL POC LIPID TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL POC LIPID TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL POC LIPID TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL POC LIPID TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL POC LIPID TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL POC LIPID TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL POC LIPID TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL POC LIPID TESTING MARKET SIZE, BY CVD RISK ASSESSMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL POC LIPID TESTING MARKET SIZE, BY CVD RISK ASSESSMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL POC LIPID TESTING MARKET SIZE, BY CVD RISK ASSESSMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL POC LIPID TESTING MARKET SIZE, BY CVD RISK ASSESSMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL POC LIPID TESTING MARKET SIZE, BY CVD RISK ASSESSMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL POC LIPID TESTING MARKET SIZE, BY CVD RISK ASSESSMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL POC LIPID TESTING MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL POC LIPID TESTING MARKET SIZE, BY PREVENTIVE SCREENING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL POC LIPID TESTING MARKET SIZE, BY PREVENTIVE SCREENING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL POC LIPID TESTING MARKET SIZE, BY PREVENTIVE SCREENING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL POC LIPID TESTING MARKET SIZE, BY PREVENTIVE SCREENING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL POC LIPID TESTING MARKET SIZE, BY PREVENTIVE SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL POC LIPID TESTING MARKET SIZE, BY PREVENTIVE SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL POC LIPID TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL POC LIPID TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 153. AMERICAS POC LIPID TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 154. AMERICAS POC LIPID TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 155. AMERICAS POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 156. AMERICAS POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 157. AMERICAS POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
• TABLE 158. AMERICAS POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
• TABLE 159. AMERICAS POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 160. AMERICAS POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 161. AMERICAS POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 162. AMERICAS POC LIPID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 163. AMERICAS POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 164. AMERICAS POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 165. AMERICAS POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 166. AMERICAS POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 167. AMERICAS POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 168. AMERICAS POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 169. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 170. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 171. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 172. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 173. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
• TABLE 174. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
• TABLE 175. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 176. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 177. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 178. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 179. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 180. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 181. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 182. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 183. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 184. NORTH AMERICA POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 185. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 186. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 187. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 188. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 189. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
• TABLE 190. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
• TABLE 191. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 192. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 193. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 194. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 195. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 196. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 197. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 198. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 199. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 200. LATIN AMERICA POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 205. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
• TABLE 206. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 210. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 211. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 212. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 213. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 214. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 215. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 216. EUROPE, MIDDLE EAST & AFRICA POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 217. EUROPE POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 218. EUROPE POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 219. EUROPE POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 220. EUROPE POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 221. EUROPE POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
• TABLE 222. EUROPE POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
• TABLE 223. EUROPE POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 224. EUROPE POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 225. EUROPE POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 226. EUROPE POC LIPID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 227. EUROPE POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 228. EUROPE POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 229. EUROPE POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 230. EUROPE POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 231. EUROPE POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 232. EUROPE POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 233. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 234. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 235. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 236. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 237. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
• TABLE 238. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
• TABLE 239. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 240. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 241. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 242. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 243. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 244. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 245. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 246. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 247. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 248. MIDDLE EAST POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 249. AFRICA POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 250. AFRICA POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 251. AFRICA POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 252. AFRICA POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 253. AFRICA POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
• TABLE 254. AFRICA POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
• TABLE 255. AFRICA POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 256. AFRICA POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 257. AFRICA POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 258. AFRICA POC LIPID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 259. AFRICA POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 260. AFRICA POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 261. AFRICA POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 262. AFRICA POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 263. AFRICA POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 264. AFRICA POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 265. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 266. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 267. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 268. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 269. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
• TABLE 270. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
• TABLE 271. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 272. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 273. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 274. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 275. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 276. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 277. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 278. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 279. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 280. ASIA-PACIFIC POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 281. GLOBAL POC LIPID TESTING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 282. GLOBAL POC LIPID TESTING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 283. ASEAN POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 284. ASEAN POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 285. ASEAN POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 286. ASEAN POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 287. ASEAN POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
• TABLE 288. ASEAN POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
• TABLE 289. ASEAN POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 290. ASEAN POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 291. ASEAN POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 292. ASEAN POC LIPID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 293. ASEAN POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 294. ASEAN POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 295. ASEAN POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 296. ASEAN POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 297. ASEAN POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 298. ASEAN POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 299. GCC POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 300. GCC POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 301. GCC POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 302. GCC POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 303. GCC POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
• TABLE 304. GCC POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
• TABLE 305. GCC POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 306. GCC POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 307. GCC POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 308. GCC POC LIPID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 309. GCC POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 310. GCC POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 311. GCC POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 312. GCC POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 313. GCC POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 314. GCC POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 315. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 316. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 317. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 318. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 319. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
• TABLE 320. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
• TABLE 321. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 322. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 323. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 324. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 325. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 326. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 327. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 328. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 329. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 330. EUROPEAN UNION POC LIPID TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 331. BRICS POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 332. BRICS POC LIPID TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 333. BRICS POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 334. BRICS POC LIPID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 335. BRICS POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
• TABLE 336. BRICS POC LIPID TESTING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
• TABLE 337. BRICS POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
• TABLE 338. BRICS POC LIPID TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
• TABLE 339. BRICS POC LIPID TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)

TAB